subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

 

CFC

 

 

 

 

 

 

 

 

 

 

Mission

Valens Therapeutics is a pharmaceutical company focused on the development of peptide-based therapeutics for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer where proliferation of new blood vessels occurs due to abnormal angiogenesis. The Company’s initial focus will be on ophthalmologic disorders which offers major opportunities for improved therapies. Valens peptide-based anti-angiogenic technology offers an alternative treatment with unique characteristics not observed in the available non-peptide based ocular therapies.

  Our Name

The name Valens, derived from Latin, means ‘strong’, ‘able’ and ‘worthwhile’. These attributes reflect the company’s ‘strong’ commitment to deliver value to patients and potential shareholders; ‘able’ environment led by trust and high levels of integrity, and ‘worthwhile’ decisions guided by value and quality.

Home | Site Map | Privacy Policy | ©2008 Valens Therapeutics, Inc. All Rights Reserved

Designed by IG-2

 Logo
Request Information|